1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Subcutaneous Self-Administration Markets to 2022 : Drugs, Devices, Therapeutics, Markets and Forecasts

As healthcare markets continue to evolve, drug developers and their supply chain partners are attempting to keep pace by addressing economic, market and therapeutic factors that increasingly revolve around how, when and where drugs are administered. This evolution is being driven by new and exciting options for patient care in the form of powerful drug therapies for treating diseases with improved outcomes and for treating diseases for which an effective treatment did not previously exist. Beyond oncology –where therapeutics continue to be supplied for administration via infusion – the majority of new non-oral drugs are being formulated for subcutaneous injection. Many of these drugs are indicated for chronic conditions, which because of the continuous need for dosing over time benefit significantly when patients can self-administer their medication. This report examines in detail the drugs, devices, therapeutics and markets that are set to change substantially over the remainder of the decade.


- Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
- Provides market data and forecasts to 2022
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
- Evaluates the impact of economic, technology, and regulatory factors

Table Of Contents

Subcutaneous Self-Administration Markets to 2022 : Drugs, Devices, Therapeutics, Markets and Forecasts
Executive Summary

Subcutaneous Drug Delivery - Market Dynamics

Subcutaneous Delivery - Why it's Growing
The Evolving Drug Pipeline
Device and Packaging Technology Advances
Shifting Patient Demographics
Healthcare Economics
Demand Drivers
The Trend toward Self-Administration
Innovation in Prefilled Device Designs
Therapeutic Targets and Treatment
Competitive Landscape
Risk Factors

SC Delivery Device Design Factors

Ergonomics and Ease of Use
Safety Features
Needle Shielding
Needle Insertion Depth
Failsafe Activation
Dose Inspection/Injection Confirmation
Lyophilized Drugs/Reconstitution

Subcutaneously Delivered Drugs - Delivery Device Strategies

Delivering Self-Administered SC Drugs
Handheld Devices
Pen Injectors
Prefilled Syringes
Other Handheld Devices
Wearable Devices
Patch Pumps
Large Volume Wearable Devices

SC Self-Administration - Product Analysis and Forecasts by Therapeutic Sector

Autoimmune Diseases
Hormone Replacement
Reproductive Health

Market Factors

Regulatory Issues
DTC Marketing
Patient Education

Company Profiles

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Europe

  • October 2016
    149 pages
  • Anti-Infective  

  • Europe  


View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.